These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 17680975)

  • 21. Partial fanconi syndrome induced by imatinib therapy: a novel cause of urinary phosphate loss.
    François H; Coppo P; Hayman JP; Fouqueray B; Mougenot B; Ronco P
    Am J Kidney Dis; 2008 Feb; 51(2):298-301. PubMed ID: 18215707
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Male patients with chronic myeloid leukemia treated with imatinib involved in healthy pregnancies: report of five cases.
    Breccia M; Cannella L; Montefusco E; Frustaci A; Pacilli M; Alimena G
    Leuk Res; 2008 Mar; 32(3):519-20. PubMed ID: 17804066
    [No Abstract]   [Full Text] [Related]  

  • 23. Imatinib mesylate induced skin hypopigmentation.
    Talwar V; Doval DC; Bhatia K
    J Assoc Physicians India; 2007 Jul; 55():527. PubMed ID: 17907508
    [No Abstract]   [Full Text] [Related]  

  • 24. Ocular side effects in chronic myeloid leukemia patients treated with imatinib.
    Breccia M; Gentilini F; Cannella L; Latagliata R; Carmosino I; Frustaci A; Alimena G
    Leuk Res; 2008 Jul; 32(7):1022-5. PubMed ID: 18061664
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Imatinib mesylate associated with delayed hematopoietic recovery after concomitant chemotherapy.
    Chand M; Thakuri M; Keung YK
    Leukemia; 2004 Apr; 18(4):886-7; author reply 887-8. PubMed ID: 14961027
    [No Abstract]   [Full Text] [Related]  

  • 26. Imatinib-induced eccrine squamous syringometaplasia.
    Van de Voorde K; De Raeve H; Van Regenmortel N; Lambert J
    J Am Acad Dermatol; 2006 Aug; 55(2 Suppl):S58-9. PubMed ID: 16843129
    [No Abstract]   [Full Text] [Related]  

  • 27. Imatinib-lnduced agranulocytosis in a patient with chronic myelogenous leukemia in remission.
    Khouri S; Kotliroff A; Lishner M; Amital H
    Isr Med Assoc J; 2008 Apr; 10(4):320-1. PubMed ID: 18548994
    [No Abstract]   [Full Text] [Related]  

  • 28. Imatinib-associated lichenoid eruption: acitretin treatment allows maintained antineoplastic effect.
    Dalmau J; Peramiquel L; Puig L; Fernández-Figueras MT; Roé E; Alomar A
    Br J Dermatol; 2006 Jun; 154(6):1213-6. PubMed ID: 16704665
    [No Abstract]   [Full Text] [Related]  

  • 29. Vitiligo-like lesions in an adult patient treated with Imatinib mesylate.
    Cerchione C; Fabbricini R; Pane F; Luciano L
    Leuk Res; 2009 Aug; 33(8):e104-5. PubMed ID: 19232719
    [No Abstract]   [Full Text] [Related]  

  • 30. [Nephrotoxicidad for imatinib].
    Díaz Rodríguez C; Vasco B
    Nefrologia; 2003; 23(3):273-4. PubMed ID: 12891946
    [No Abstract]   [Full Text] [Related]  

  • 31. Catastrophic tumour lysis syndrome following single dose of imatinib.
    Keane C; Henden A; Bird R
    Eur J Haematol; 2009 Mar; 82(3):244-5. PubMed ID: 19067739
    [No Abstract]   [Full Text] [Related]  

  • 32. Peritoneal tuberculosis after imatinib therapy.
    Senn L; Kovacsovics T; Tarr PE; Meylan P
    Arch Intern Med; 2009 Feb; 169(3):312-3. PubMed ID: 19204223
    [No Abstract]   [Full Text] [Related]  

  • 33. Ketoconazole therapy and exfoliative erythroderma.
    Rand R; Sober AJ; Olmstead PM
    Arch Dermatol; 1983 Feb; 119(2):97-8. PubMed ID: 6297411
    [No Abstract]   [Full Text] [Related]  

  • 34. Sustained complete molecular remission after imatinib discontinuation due to severe aplastic anemia.
    Hernández-Boluda JC; Collado M; Roda D; Amat P; Tormo M; Marugán I
    Leuk Res; 2009 Apr; 33(4):589-92. PubMed ID: 18817972
    [No Abstract]   [Full Text] [Related]  

  • 35. Is imatinib safe during pregnancy?
    Dolai TK; Bhargava R; Mahapatra M; Mishra P; Seth T; Pati HP; Saxena R
    Leuk Res; 2009 Apr; 33(4):572-3. PubMed ID: 18789526
    [No Abstract]   [Full Text] [Related]  

  • 36. Systemic Mastocytosis: documented pathologic response to imatinib.
    Gollard RP; Ruemmler-Fish C; Garcia D
    Eur J Haematol; 2007 Oct; 79(4):367-8. PubMed ID: 17655701
    [No Abstract]   [Full Text] [Related]  

  • 37. Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an Italian Multicentric Phase II Study.
    Piccaluga PP; Malagola M; Rondoni M; Arpinati M; Paolini S; Candoni A; Fanin R; Messa E; Pirrotta MT; Lauria F; Visani G; Alberti D; Rancati F; Vinaccia V; Russo D; Saglio G; Baccarani M; Martinelli G
    Haematologica; 2007 Dec; 92(12):1721-2. PubMed ID: 18056005
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lymphomatoid granulomatosis induced by imatinib-treatment.
    Yazdi AS; Metzler G; Weyrauch S; Berneburg M; Bitzer M; Müller-Hermelink HK; Röcken M
    Arch Dermatol; 2007 Sep; 143(9):1222-3. PubMed ID: 17875901
    [No Abstract]   [Full Text] [Related]  

  • 39. Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients.
    Burke MJ; Trotz B; Luo X; Weisdorf DJ; Baker KS; Wagner JE; Verneris MR
    Bone Marrow Transplant; 2009 Aug; 44(3):169-74. PubMed ID: 19204709
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Imatinib Mesylate Induced Erythroderma.
    Lunge S; Bhise R
    J Assoc Physicians India; 2018 Dec; 66(12):79-80. PubMed ID: 31313559
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.